Floatz logo

20 assets in Bile Duct Cancer

Therapeutic assets addressing Bile Duct Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Bile Duct Cancer
Lisata Therapeutics, Inc.P2BB (64)
Oxaliplatin
Bile Duct Cancer
Lisata Therapeutics, Inc.P2B (62)
Fluorouracilum
Bile Duct Cancer
Lisata Therapeutics, Inc.P2B (60)
N-Butyl Cyanoacrylate
Bile Duct Cancer
Minia UniversityP3B (60)
Pembrolizumab
Bile Duct Cancer
Imugene LimitedP2B (60)
Durvalumab
Bile Duct Cancer
Lisata Therapeutics, Inc.P2B (57)
Dexasone
Bile Duct Cancer
National Cancer Institute (NCI)P2CCC (53)
Floxuridine
Bile Duct Cancer
National Cancer Institute (NCI)P2CCC (53)
pds01adc
Bile Duct Cancer
National Cancer Institute (NCI)P2CCC (53)
Utidelone
Bile Duct Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.P2CCC (53)
Irinotecan
Bile Duct Cancer
University Hospital, GhentP1CCC (50)
Certepetide
Bile Duct Cancer
Lisata Therapeutics, Inc.P2CCC (49)
Atezolizumab
Bile Duct Cancer
University of FloridaP1/2CC (47)
Tivozanib
Bile Duct Cancer
University of FloridaP1/2CC (47)
Eli-002 7P
Bile Duct Cancer
Elicio TherapeuticsP1CC (46)
ai-061
Bile Duct Cancer
OncoC4, Inc.P1CC (43)
Cea-Targeted Car-T
Bile Duct Cancer
Chongqing Precision Biotech Co., LtdP1CC (43)
cf33-hnis
Bile Duct Cancer
Imugene LimitedP1CC (43)
kj015
Bile Duct Cancer
Shanghai Bao Pharmaceuticals Co., Ltd.P1CC (43)
Ucmym802
Bile Duct Cancer
UTC Therapeutics Inc.P1CC (43)